A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months

Susanna Esposito, Paola Marchisio, Filippo Ansaldi, Sonia Bianchini, Michela Pacei, Elena Baggi, Daria Trabattoni, Giancarlo Icardi, Nicola Principi

Research output: Contribution to journalArticle


This study evaluated the immunogenicity of a double dose of the seasonal virosomal-adjuvanted influenza vaccine (Inflexal V, Crucell, The Netherlands) in 65 previously unvaccinated children aged less than 3 years: 43 received double doses (two doses of 0.50. mL 4 weeks apart) and 22 standard doses (two doses of 0.25. mL 4 weeks apart). Both treatments evoked a response that satisfied the EMEA criteria for adequate immunogenicity for all three vaccine strains, but the double dose had a significantly greater effect on all of the studied parameters of humoral and cell-mediated immune response (p

Original languageEnglish
Pages (from-to)6137-6144
Number of pages8
Issue number38
Publication statusPublished - Aug 2010



  • Children
  • Immunogenicity
  • Influenza
  • Influenza vaccine
  • Reactogenicity
  • Virosomal

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this